ResMed Inc.(纽约证券交易所代码：RMD)内部人士David Pendarvis出售1,545股票

ResMed Inc. (NYSE:RMD – Get Rating) insider David Pendarvis sold 1,545 shares of the firm's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $212.33, for a total value of $328,049.85. Following the transaction, the insider now directly owns 106,831 shares of the company's stock, valued at approximately $22,683,426.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

David Pendarvis also recently made the following trade(s):

Get

ResMed

alerts:

• On Friday, June 3rd, David Pendarvis sold 1,545 shares of ResMed stock. The shares were sold at an average price of $209.44, for a total value of $323,584.80.
• On Tuesday, May 3rd, David Pendarvis sold 1,545 shares of ResMed stock. The shares were sold at an average price of $200.00, for a total value of $309,000.00.

NYSE RMD traded up $0.86 during trading hours on Wednesday, hitting $217.29. The company's stock had a trading volume of 781,913 shares, compared to its average volume of 606,051. ResMed Inc. has a 12 month low of $189.40 and a 12 month high of $301.34. The company's 50 day simple moving average is $203.87 and its two-hundred day simple moving average is $229.43. The company has a market cap of $31.79 billion, a P/E ratio of 40.92, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.55 and a quick ratio of 1.56.

ResMed (NYSE:RMD – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The medical equipment provider reported $1.32 EPS for the quarter, missing the consensus estimate of $1.44 by ($0.12). ResMed had a return on equity of 26.91% and a net margin of 22.02%. The business had revenue of $864.50 million during the quarter, compared to the consensus estimate of $900.03 million. During the same quarter in the previous year, the business posted $1.30 earnings per share. ResMed's quarterly revenue was up 12.4% compared to the same quarter last year. As a group, research analysts predict that ResMed Inc. will post 5.74 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 16th. Investors of record on Thursday, May 12th were issued a $0.42 dividend. The ex-dividend date of this dividend was Wednesday, May 11th. This represents a $1.68 annualized dividend and a yield of 0.77%. ResMed's payout ratio is 31.64%.

Several equities analysts have commented on the company. Wolfe Research assumed coverage on ResMed in a research report on Tuesday, April 5th. They set an "outperform" rating and a $280.00 price objective for the company. StockNews.com lowered ResMed from a "buy" rating to a "hold" rating in a research report on Thursday, June 16th. Finally, Royal Bank of Canada raised ResMed from a "sector perform" rating to an "outperform" rating and lifted their price target for the stock from $233.00 to $244.00 in a research report on Monday, June 6th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $260.67.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RMD. Comprehensive Financial Consultants Institutional Inc. bought a new stake in shares of ResMed during the 4th quarter valued at about $25,000. Amplius Wealth Advisors LLC bought a new stake in shares of ResMed during the 4th quarter valued at about $26,000. CVA Family Office LLC bought a new stake in shares of ResMed during the 4th quarter valued at about $31,000. GHP Investment Advisors Inc. bought a new stake in shares of ResMed during the 1st quarter valued at about $33,000. Finally, Capital Advisors Ltd. LLC bought a new stake in shares of ResMed during the 4th quarter valued at about $39,000. Institutional investors own 65.24% of the company's stock.

ResMed Company Profile (Get Rating)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

See Also

• Get a free copy of the StockNews.com research report on ResMed (RMD)
• Recession Resistant Grocery Outlet Holding Corp Quietly Sets New High
• It's Not Too Late For These Undervalued Energy Stocks
• Three Cheap Stocks That Just Got Upgraded
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Get Defensive With These Three Upgrades

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.